Trials / Recruiting
RecruitingNCT06090110
Vagal Nerve Stimulation in Irritable Bowel Syndrome
Clinical Efficacy of Transcutaneous Auricular Vagal Nerve Stimulation in Irritable Bowel Syndrome and the Potential Predictive Role for the Vagal-Autonomic Neurosignature
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 166 (estimated)
- Sponsor
- Maastricht University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This randomized control trial aims to evaluate the effect of transcutaneous auricular vagal nerve stimulation in patients with irritable bowel syndrome. The intervention will be 8 weeks of treatment with a vagal nerve stimulator. The main objectives are: * To evaluate the clinical response, defined as a decrease of at least 50 points on the IBS-SSS questionnaire, of the treatment. * To ascertain whether the autonomic-vagal neurosignature, derived from pre-treatment registration of symptom profiles, autonomic responses and imaging of neuronal activity as a reaction to stress is able to predict therapeutic response to tVNS accurately. * To evaluate the effect of treatment on quality of life * To evaluate the effect of treatment on depression * To evaluate the effect of treatment on anxiety Participants will be asked to wear a wearable (Fitbit) and fill out a daily questionnaire for one week. Thereafter, a functional brain MRI will be performed. In the intervention group patients will receive transcutaneous nerve stimulation for 8-weeks at home. The comparison group will receive the same device but with a non-conducting electrode. Patients fill out weekly questionnaires during the treatment period and at follow-up moments 3 and 6 months after finishing the treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Vagal Nerve Stimulation | Transcutaneous Auricular Vagal Nerve Stimulation |
| DEVICE | Sham stimulation | Sham stimulation with a non-conduction electrode |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2025-11-01
- Completion
- 2026-11-01
- First posted
- 2023-10-19
- Last updated
- 2024-08-02
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT06090110. Inclusion in this directory is not an endorsement.